...Thank you. And before I start, I really want to say thank you to all of our stakeholders as Q2 was a big unknown for everyone when we look back to March. We weren't sure how bad revenue Rxs would decline or how our cash position would be impacted or TreT would be slowed down and for how long. Our team, whether it be HR, finance, R&D, manufacturing, medical or sales, pulled through big time, as we will discuss here in our earnings call today, and we are now finally in a very solid financial position as we look ahead. I'm very excited about our future, whether it be the international expansion, TreT filings, the Tyvaso data readout in COPD and the incredible foundation of Afrezza we can build our future growth upon. The talent and interest in MannKind is very high right now, and the bench of diabetes expertise continues to grow each day. Thank you, again, to our employees, our patients, our customers and our shareholders for hanging in there during what could have been one of the darkest...
